Provided by Tiger Trade Technology Pte. Ltd.

HANGZHOU TIGERMED CONSULTING CO LTD.

4.00
0.0000
Volume:- -
Turnover:- -
Market Cap:3.45B
PE:74.66
High:4.00
Open:4.00
Low:4.00
Close:4.00
52wk High:4.00
52wk Low:4.00
Shares:861.29M
Float Shares:622.16M
Volume Ratio:0.53
T/O Rate:- -
Dividend:0.04
Dividend Rate:1.05%
EPS(TTM):0.0536
EPS(LYR):0.0643
ROE:2.59%
ROA:1.06%
PB:1.12
PE(LYR):62.19

Loading ...

Company Profile

Company Name:
HANGZHOU TIGERMED CONSULTING CO LTD.
Exchange:
PINK LIMITED
Establishment Date:
2004
Employees:
10185
Office Location:
Shengda Science Park, Building A,Floor 18,No.19 Jugong Road,Binjiang District,Hangzhou,Zhejiang Province,China
Zip Code:
310051
Fax:
- -
Introduction:
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.